CorePath Laboratories Announces Partnership with Cizzle Biotechnology to Develop Simple Blood Test for Early Detection of Lung Cancer


The American Cancer Society estimates for lung cancer in United States for 2022 are as follows:

  • Approximately 236,740 new cases of lung cancer (117,910 in men and 118,830 in women) each year.*
  • Approximately 130,180 lung cancer deaths (68,820 in men and 61,360 in women) each year.*
  • Currently, there are no simple, specific blood tests to detect lung cancer at an early stage when targeted interventions can improve timely access to cancer care and save lives. Yet it is estimated that approximately eight million Americans are considered at high risk for lung cancer and are recommended to be screened annually with low dose CT scans and if half of these high risk individuals were screened, more than 12,000 lung cancer deaths could be prevented.* *

Commenting, Dr. Aamir EhsanCEO and Chief Medical Officer of CorePath, said:
“As a board-certified hematopathologist and molecular geneticist; diagnosing cancer hurts, especially when cancer has already metastasized in patients. As efforts are underway to find active genetic mutations to target treatment and improve survival, early detection and intervention are essential for long-term patients.The agreement with Cizzle Biotechnology represents a significant opportunity to provide early and cost-effective detection of lung cancer via a simple and quickly, which will lead to significant downstream savings, avoiding costly treatments, hospital admissions and ultimately saving lives.”

Commenting, Allan SymExecutive Chairman of Cizzle Biotechnology, said:
“Lung cancer is the leading cause of cancer death in the UNITED STATES and a major global health problem. Indeed, for many, detection of lung cancer does not occur until it has become symptomatic and therefore more advanced, which means that 5-year survival rates are low. The Company’s CIZ1B biomarker for detecting lung cancer at an early stage could represent a major breakthrough and now we have the opportunity to bring the benefits of this test to such a large market. We are excited to partner with CorePath Laboratories who bring the specialist knowledge and market reach to help develop our biomarker into a certified test that can be made available to patients and healthcare providers around the world. UNITED STATES.”

About CorePath Labs
CorePath is a Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP) accredited laboratory headquartered in San Antonio, TX. CorePath is one of the few international laboratories able to offer immunohistochemistry, cancer genetics and multi-color flow cytometry services at a single location. CorePath provides a wide range of oncology pathology services to healthcare providers in the UNITED STATES and internationally. CorePath is comprised of board-certified pathologists and clinical laboratory scientists with multi-specialty expertise in cancer pathology who compassionately use state-of-the-art technology to accurately diagnose cancers and achieve the most accurate results in a timely manner. for early treatment.

CorePath’s biopharmaceutical division is a highly specialized team with a common passion: “Caring for Lives”.

For more information, visit https://www.corepath.us/

About Cizzle Biotechnology
Cizzle Biotechnology is developing a blood test for the early detection of lung cancer. Cizzle Biotechnology is a University of York spin-off, founded in 2006 around the work of Professor Coverley and his colleagues. Its prototype proof-of-concept test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cellular nuclear protein involved in DNA replication, and the targeted variant of CIZ1B is strongly correlated with early-stage lung cancer.

For more information visit https://cizzlebiotechnology.com

References
* https://www.cancer.org/cancer/lung-cancer/about/key-statistics.html

** Cheung LC, Katki HA, Chaturvedi AK, Jemal A, Berg CD. Preventing Lung Cancer Mortality by CT Screening: The Effect of Task Force Eligibility Criteria on Risk-Based Preventive Services Compared to the United States, 2005-2015. Annals of Internal Medicine. 2018; 168(3):229-32. doi:10.7326/M17-2067.

SOURCE CorePath Laboratories

Previous 7thonline, Anaplan, Aptos, Armonica Retail, Blue Yonder, Board International – The Daily Vale
Next RPT: Evidence Shows US Pursuing Biological Research in Indonesia Despite Lab Ban